Overview

Combination regimens succeed when the right patients are chosen, and PD-L1 expression is a practical gate for pairing immune therapy with other treatments. The E1L3N IHC clone provides a consistent Tumor Proportion Score that clinicians use to weigh adding checkpoint inhibition to chemotherapy or to a second agent. This makes the assay a logistical anchor for combination-treatment planning.

How It Works

The E1L3N antibody is applied to FFPE sections through a validated staining process, and membrane staining on viable tumor cells is scored as a percentage. Because the clone is widely adopted, results are comparable across many laboratories that follow the standard protocol. The reported TPS is interpreted together with the treatment plan rather than in isolation.

Indications

The assay supports evaluation of patients being considered for combination approaches that include PD-1 or PD-L1 pathway inhibitors. It is relevant where a higher PD-L1 score predicts added benefit from combining immunotherapy with cytotoxic or targeted partners. Timing the test before treatment initiation lets teams sequence the full regimen confidently.

Specimen & Reporting

A representative FFPE block delivers the needed material, and the report states the TPS alongside the clone and platform. Turnaround is generally 5–7 working days. Clear documentation lets the treating team map the score to the combination regimen under discussion.

Storage & Sourcing

Slides travel at ambient temperature with desiccant and are stained soon after arrival. For centers building combination-therapy pathways, scheduled batch testing keeps the biomarker step from delaying treatment start. Give Life Time International supplies the E1L3N service with consistent reagents so combination programs can scale. A standing specimen-collection protocol across sites keeps the assay comparable and lets multidisciplinary teams plan combination starts without waiting on repeat testing.

FAQ

Q: Why is PD-L1 testing done before starting a combination regimen? The score helps predict whether adding immune therapy to chemotherapy or another agent is likely to improve outcomes for that patient.

Q: Does a low E1L3N score rule out combination treatment? Not always; many combination labels allow treatment regardless of score, while the result refines the expected benefit and discussion.

Q: How does E1L3N compare with 22C3 for combination planning? They are different clones with distinct validated contexts, so the clone tied to the specific regimen should be used.

Q: Can the same block support combination-therapy and genomic testing? Yes, provided tumor content allows; separate sections are prepared for IHC and for molecular work.